146 related articles for article (PubMed ID: 35073648)
1. [Chinese expert consensus on multigene testing for postoperatively adjuvant treatment of hormone receptor-positive, HER2-negative early breast cancer].
;
Zhonghua Zhong Liu Za Zhi; 2022 Jan; 44(1):54-59. PubMed ID: 35073648
[TBL] [Abstract][Full Text] [Related]
2. [Chinese expert consensus on multigene testing for adjuvant treatment of HR-positive, HER-2 negative early breast cancer(2023 edition)].
;
Zhonghua Zhong Liu Za Zhi; 2023 Oct; 45(10):863-870. PubMed ID: 37875422
[TBL] [Abstract][Full Text] [Related]
3. Molecular Profiling in Early ER + Breast Cancer to Aid Systemic Therapy Decisions.
Gluz O; Graeser M
Curr Oncol Rep; 2023 May; 25(5):491-500. PubMed ID: 36862337
[TBL] [Abstract][Full Text] [Related]
4. Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost-effectiveness analysis.
Ward S; Scope A; Rafia R; Pandor A; Harnan S; Evans P; Wyld L
Health Technol Assess; 2013 Oct; 17(44):1-302. PubMed ID: 24088296
[TBL] [Abstract][Full Text] [Related]
5. Multigene testing in breast cancer: What have we learned from the 21-gene recurrence score assay?
Turashvili G; Wen HY
Breast J; 2020 Jun; 26(6):1199-1207. PubMed ID: 32458521
[TBL] [Abstract][Full Text] [Related]
6. The concordance of treatment decision guided by OncotypeDX and the PREDICT tool in real-world early-stage breast cancer.
Goldstein DA; Mayer C; Shochat T; Reinhorn D; Moore A; Sarfaty M; Yerushalmi R; Goldvaser H
Cancer Med; 2020 Jul; 9(13):4603-4612. PubMed ID: 32372569
[TBL] [Abstract][Full Text] [Related]
7. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update.
Krop I; Ismaila N; Andre F; Bast RC; Barlow W; Collyar DE; Hammond ME; Kuderer NM; Liu MC; Mennel RG; Van Poznak C; Wolff AC; Stearns V
J Clin Oncol; 2017 Aug; 35(24):2838-2847. PubMed ID: 28692382
[TBL] [Abstract][Full Text] [Related]
8. The Evolving Complexity of Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer: Special Considerations in Older Breast Cancer Patients-Part I: Early-Stage Disease.
Sammons S; Sedrak MS; Kimmick GG
Drugs Aging; 2020 May; 37(5):331-348. PubMed ID: 32100240
[TBL] [Abstract][Full Text] [Related]
9. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis.
Harnan S; Tappenden P; Cooper K; Stevens J; Bessey A; Rafia R; Ward S; Wong R; Stein RC; Brown J
Health Technol Assess; 2019 Jun; 23(30):1-328. PubMed ID: 31264581
[TBL] [Abstract][Full Text] [Related]
10. Application Of Multigene Panel Detection In Breast Cancer.
Zhao Y; Xiong D; Yang B; Xia S; Zhang X
J Pak Med Assoc; 2023 Sep; 73(9):1862-1868. PubMed ID: 37817699
[TBL] [Abstract][Full Text] [Related]
11. The multigene classifiers 95GC/42GC/155GC for precision medicine in ER-positive HER2-negative early breast cancer.
Naoi Y; Tsunashima R; Shimazu K; Noguchi S
Cancer Sci; 2021 Apr; 112(4):1369-1375. PubMed ID: 33544932
[TBL] [Abstract][Full Text] [Related]
12. OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer.
Stein RC; Dunn JA; Bartlett JM; Campbell AF; Marshall A; Hall P; Rooshenas L; Morgan A; Poole C; Pinder SE; Cameron DA; Stallard N; Donovan JL; McCabe C; Hughes-Davies L; Makris A;
Health Technol Assess; 2016 Feb; 20(10):xxiii-xxix, 1-201. PubMed ID: 26867046
[TBL] [Abstract][Full Text] [Related]
13. Are we Overtreating Hormone Receptor Positive Breast Cancer with Neoadjuvant Chemotherapy? Role of OncotypeDx
Kantor O; Barrera E; Kopkash K; Pesce C; Barrera E; Winchester DJ; Yao K
Ann Surg Oncol; 2019 Oct; 26(10):3232-3239. PubMed ID: 31342379
[TBL] [Abstract][Full Text] [Related]
14. The MAGIC survey in hormone receptor positive (HR+), HER2-negative (HER2-) breast cancer: When might multigene assays be of value?
Aapro M; De Laurentiis M; Rea D; Bargallo Rocha JE; Elizalde R; Landherr L; Linderholm B; Mamounas E; Markopoulos C; Neven P; Petrovsky A; Rouzier R; Smit V; Svedman C; Schneider D; Thomssen C; Martin M
Breast; 2017 Jun; 33():191-199. PubMed ID: 28441617
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathologic analysis of 722 breast cancer patients who met the inclusion criteria of the TAILORx trial.
Xiang HY; Liu YH; Zhang H; Zhang S; Xin L; Xu L; Ye JM; Li T; Duan XN; Liu Q
Chin Med J (Engl); 2019 Dec; 132(24):2914-2919. PubMed ID: 31809316
[TBL] [Abstract][Full Text] [Related]
16. Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapy.
Du L; Yau C; Brown-Swigart L; Gould R; Krings G; Hirst GL; Bedrosian I; Layman RM; Carter JM; Klein M; Venters S; Shad S; van der Noordaa M; Chien AJ; Haddad T; Isaacs C; Pusztai L; Albain K; Nanda R; Tripathy D; Liu MC; Boughey J; Schwab R; Hylton N; DeMichele A; Perlmutter J; Yee D; Berry D; Van't Veer L; Valero V; Esserman LJ; Symmans WF
Ann Oncol; 2021 May; 32(5):642-651. PubMed ID: 33617937
[TBL] [Abstract][Full Text] [Related]
17. Impact of a 21-Gene Recurrence Score Test on the Choice of Adjuvant Chemotherapy for Hormone Receptor-positive Early-stage Breast Cancer: A Prospective Study.
Zeng Y; Li Q; Qin T; Li S; Jin L; Wu J; Chen K; Deng H; Rao N; Liu Q; Su F; Jia W; Yao H
Anticancer Res; 2017 Aug; 37(8):4539-4547. PubMed ID: 28739750
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer assessment tools and optimizing adjuvant therapy.
Oakman C; Santarpia L; Di Leo A
Nat Rev Clin Oncol; 2010 Dec; 7(12):725-32. PubMed ID: 20975745
[TBL] [Abstract][Full Text] [Related]
19. Consensus guidelines for the management of HR-positive HER2/neu negative early breast cancer in India, SAARC region and other LMIC by DELPHI survey method.
Parikh P; Babu G; Singh R; Krishna V; Bhatt A; Bansal I; Rajappa S; Sahoo TP; Aggarwal S; Bapna A; Biswas G; Somashekhar SP; Bajpai J; Maniar V; Desai S; Raja T; Rath GK
BMC Cancer; 2023 Jul; 23(1):714. PubMed ID: 37525142
[TBL] [Abstract][Full Text] [Related]
20. The IHC4+C score: an affordable and reproducible non-molecular decision-aid in hormone receptor-positive breast cancer. Does it still hold value for patients in 2020?
Harel N; Cheema S; Williams D; Ireland-Jenkin K; Fancourt T; Dodson A; Yeo B
Asia Pac J Clin Oncol; 2021 Aug; 17(4):368-376. PubMed ID: 33567144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
